Market Cap 5.35B
Revenue (ttm) 434.43M
Net Income (ttm) 275.19M
EPS (ttm) N/A
PE Ratio 134.24
Forward PE N/A
Profit Margin 63.35%
Debt to Equity Ratio 0.00
Volume 1,360,700
Avg Vol 1,295,654
Day's Range N/A - N/A
Shares Out 62.52M
Stochastic %K 82%
Beta 2.22
Analysts Strong Sell
Price Target $87.38

Company Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 474 0170
Address:
7707 Gateway Boulevard, Suite 140, Newark, United States
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:40 AM
$PTGX is currently trading at $85.56, exhibiting a strong bullish trend indicated by an RSI of 78.02, suggesting overbought conditions. The price is above both the 30-day MA of 74.97 and the 50-day MA of 69.56, reinforcing the bullish momentum. However, the elevated RSI indicates potential for a pullback. Given the 60-day high of $93.25, there is room for upward movement, but caution is warranted due to the risk of a correction. A suggested entry point could be around $84.00, anticipating a small retracement. A stop-loss can be placed at $81.50 to manage risk. Targets are set at $90.00 and $93.00, aligning with the recent high and providing a favorable risk-reward ratio. Monitor the RSI for signs of divergence as the trade progresses. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
blueb22
blueb22 Nov. 12 at 3:32 AM
$PTGX - J&J will have to now rush to finish negotiations and announce BO. They can not wait longer, otherwise will have to pay higher valuation as SP is in consistent uptrend in last few days. rotation into Biotech is and will help here as well. Hope for the best. youtube.com/watch%3Fv%3Dh1Q......
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:16 AM
$PTGX is currently trading at $85.56, exhibiting a strong bullish trend indicated by an RSI of 78.02, suggesting overbought conditions. The price is above both the 30-day MA of 74.97 and the 50-day MA of 69.56, reinforcing the bullish momentum. However, the elevated RSI indicates potential for a pullback. Given the 60-day high of $93.25, there is room for upward movement, but caution is warranted due to the risk of a correction. A suggested entry point could be around $84.00, anticipating a small retracement. A stop-loss can be placed at $81.50 to manage risk. Targets are set at $90.00 and $93.00, aligning with the recent high and providing a favorable risk-reward ratio. Monitor the RSI for signs of divergence as the trade progresses. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 9:56 PM
Citigroup has updated their rating for Protagonist Therapeutics ( $PTGX ) to Buy with a price target of 98.
0 · Reply
blueb22
blueb22 Nov. 10 at 5:27 PM
$VKTX $SRPT $PTGX $BEAM $NTLA - In JPM Healthcare conferences 13-14 Jan 2026, featured sessions include "Pharma's Big Bet and the Resurgence of M&A", "Next-gen Partnerships: Unlocking Speed, Scale, and Value in Clinical Development", and most important for VKTX (and metabolic players) is "GLP-1s and the Next Waves in Obesity Therapies" Will be very interesting. And bullish for VKTX
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 10 at 1:30 PM
$IFRX $PTGX congrats to all investors. i reiterate that i think a fixed-dosed combination w/ an il17a/f would be a game changer.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 8:09 PM
JP Morgan has updated their rating for Protagonist Therapeutics ( $PTGX ) to Overweight with a price target of 81.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 3:48 PM
Barclays updates rating for Protagonist Therapeutics ( $PTGX ) to Overweight, target set at 72 → 88.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 2:13 PM
Citizens updates rating for Protagonist Therapeutics ( $PTGX ) to Market Outperform, target set at 69 → 102.
0 · Reply
Quantumup
Quantumup Nov. 7 at 11:47 AM
Clear Street⬆️ $PTGX to $91/reitd Buy $TAK $JNJ $ABBV $ABVX Clear Street said: Model Update - we're increasing our PT to $91 from $74. Our revised model increases peak penetration for rusfertide in polycythemia vera (PV) to 25% (from 20%), driven by the drug's convenient self-administration (and auto-injector) potential, which could significantly enhance patient adherence and uptake. We're also increasing our POS for the Crohn's disease market model to 75% from 50%, despite not yet seeing any data for this indication. This adjustment is based on precedent: although Crohn's remains a more challenging target, drugs that succeed in UC frequently demonstrate efficacy in Crohn's, whereas failure in UC seldom justifies continued Crohn's development. Notably, industry leaders in IL-23 inhibition-STELARA (ustekinumab) and SKYRIZI-achieved their best clinical outcomes in Crohn's after initially establishing evidence in UC, with early Crohn's decisions made before patient-level data were available.
0 · Reply
Latest News on PTGX
Johnson & Johnson in Talks to Buy Protagonist Therapeutics

Oct 10, 2025, 11:13 AM EDT - 4 weeks ago

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

JNJ


Protagonist Therapeutics Reports Granting of Inducement Award

Apr 16, 2025, 4:05 PM EDT - 7 months ago

Protagonist Therapeutics Reports Granting of Inducement Award


Overlooked Stock: PTGX

Mar 10, 2025, 4:57 PM EDT - 8 months ago

Overlooked Stock: PTGX


Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Mar 10, 2025, 10:04 AM EDT - 8 months ago

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?


Protagonist Therapeutics Reports Granting of Inducement Awards

Jan 6, 2025, 4:05 PM EST - 11 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards


PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:40 AM
$PTGX is currently trading at $85.56, exhibiting a strong bullish trend indicated by an RSI of 78.02, suggesting overbought conditions. The price is above both the 30-day MA of 74.97 and the 50-day MA of 69.56, reinforcing the bullish momentum. However, the elevated RSI indicates potential for a pullback. Given the 60-day high of $93.25, there is room for upward movement, but caution is warranted due to the risk of a correction. A suggested entry point could be around $84.00, anticipating a small retracement. A stop-loss can be placed at $81.50 to manage risk. Targets are set at $90.00 and $93.00, aligning with the recent high and providing a favorable risk-reward ratio. Monitor the RSI for signs of divergence as the trade progresses. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
blueb22
blueb22 Nov. 12 at 3:32 AM
$PTGX - J&J will have to now rush to finish negotiations and announce BO. They can not wait longer, otherwise will have to pay higher valuation as SP is in consistent uptrend in last few days. rotation into Biotech is and will help here as well. Hope for the best. youtube.com/watch%3Fv%3Dh1Q......
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:16 AM
$PTGX is currently trading at $85.56, exhibiting a strong bullish trend indicated by an RSI of 78.02, suggesting overbought conditions. The price is above both the 30-day MA of 74.97 and the 50-day MA of 69.56, reinforcing the bullish momentum. However, the elevated RSI indicates potential for a pullback. Given the 60-day high of $93.25, there is room for upward movement, but caution is warranted due to the risk of a correction. A suggested entry point could be around $84.00, anticipating a small retracement. A stop-loss can be placed at $81.50 to manage risk. Targets are set at $90.00 and $93.00, aligning with the recent high and providing a favorable risk-reward ratio. Monitor the RSI for signs of divergence as the trade progresses. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 9:56 PM
Citigroup has updated their rating for Protagonist Therapeutics ( $PTGX ) to Buy with a price target of 98.
0 · Reply
blueb22
blueb22 Nov. 10 at 5:27 PM
$VKTX $SRPT $PTGX $BEAM $NTLA - In JPM Healthcare conferences 13-14 Jan 2026, featured sessions include "Pharma's Big Bet and the Resurgence of M&A", "Next-gen Partnerships: Unlocking Speed, Scale, and Value in Clinical Development", and most important for VKTX (and metabolic players) is "GLP-1s and the Next Waves in Obesity Therapies" Will be very interesting. And bullish for VKTX
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 10 at 1:30 PM
$IFRX $PTGX congrats to all investors. i reiterate that i think a fixed-dosed combination w/ an il17a/f would be a game changer.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 8:09 PM
JP Morgan has updated their rating for Protagonist Therapeutics ( $PTGX ) to Overweight with a price target of 81.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 3:48 PM
Barclays updates rating for Protagonist Therapeutics ( $PTGX ) to Overweight, target set at 72 → 88.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 2:13 PM
Citizens updates rating for Protagonist Therapeutics ( $PTGX ) to Market Outperform, target set at 69 → 102.
0 · Reply
Quantumup
Quantumup Nov. 7 at 11:47 AM
Clear Street⬆️ $PTGX to $91/reitd Buy $TAK $JNJ $ABBV $ABVX Clear Street said: Model Update - we're increasing our PT to $91 from $74. Our revised model increases peak penetration for rusfertide in polycythemia vera (PV) to 25% (from 20%), driven by the drug's convenient self-administration (and auto-injector) potential, which could significantly enhance patient adherence and uptake. We're also increasing our POS for the Crohn's disease market model to 75% from 50%, despite not yet seeing any data for this indication. This adjustment is based on precedent: although Crohn's remains a more challenging target, drugs that succeed in UC frequently demonstrate efficacy in Crohn's, whereas failure in UC seldom justifies continued Crohn's development. Notably, industry leaders in IL-23 inhibition-STELARA (ustekinumab) and SKYRIZI-achieved their best clinical outcomes in Crohn's after initially establishing evidence in UC, with early Crohn's decisions made before patient-level data were available.
0 · Reply
d_risk
d_risk Nov. 7 at 12:50 AM
$PTGX - Protagonist Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors PTGX flags new risks from potential FDA/government disruptions, macroeconomic instability (inflation, tariffs, trade policy), and ongoing stock price volatility, all of which could seriously impact its business and valuation. #Biotechnology #PharmaceuticalIndustry #StockVolatility #MacroeconomicInstability #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/PTGX/10-Q/2025-11-06
0 · Reply
justiceforb_85
justiceforb_85 Nov. 6 at 1:47 AM
$PTGX outstanding data for icotrokinra in plaque psoriasis. This should be worth much more, especially if oral IL-17 agent is successful. https://www.nejm.org/doi/full/10.1056/NEJMoa2504187?query=featured_home
0 · Reply
Quantumup
Quantumup Nov. 4 at 11:23 AM
Citizens reiterated $ABVX Market Outperform/$114 $PTGX - $JNJ $ABBV $LLY PFE Citizens JMP said in its note: Additional data from the Phase 3 ABTECT induction studies underscore improvement in quality of life with obefazimod treatment; we reiterate our Market Outperform rating and $114 risk-adjusted, DCF-derived price target on Abivax. Yesterday afternoon, Abivax announced patient-reported data from the Phase 3 ABTECT induction studies underscoring an improvement in patient quality of life with obefazimod treatment. In our view, these results support high patient compliance and reinforce our view in the differentiated clinical profile of obefazimod.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 2 at 12:54 AM
showing why i wait for H% to reset on $PTGX before entering
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 1 at 10:23 PM
$IFRX i wish inflarx and $PTGX would join forces for hs. i think an oral c5aR1 inhibitor + il-17a/f would be a super combo for treating hs among other il-17 driven autoimmune diseases.
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 30 at 10:47 PM
$PTGX new pys estimates for ico from leerink.
0 · Reply
blueb22
blueb22 Oct. 29 at 2:36 AM
$PTGX - it is up total 6% (4.3% during regular hours + 1.8% AH), and latest updated UC Phase 2b results at 28 week is great, and many analysts increased PT.... It looks like time is near for J&J to announce buyout. Hope they do not sale for less than $100.
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 27 at 11:43 AM
$PTGX time for $JNJ to pay up!! https://www.prnewswire.com/news-releases/icotrokinra-maintains-standout-combination-of-therapeutic-benefit-and-a-favorable-safety-profile-in-once-daily-pill-through-28-weeks-in-ulcerative-colitis-302594371.html
0 · Reply
tic2tape
tic2tape Oct. 24 at 6:47 PM
@JFais $PTGX Do you cover this one? Do you think it is BO? Thanks
1 · Reply
Trapjaw
Trapjaw Oct. 24 at 11:31 AM
$AVTX Cantor #Biotechnology: Today @ 2 PM ET - Panel Discussion with Leading Dermatologists $AVTX $PTGX
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
Camelinvesting
Camelinvesting Oct. 19 at 2:52 PM
$PTGX charte looks decent! Primes for continuation upwards imo
0 · Reply